Cargando…
S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
BACKGROUND: Activation of indirect pathway medium spiny neurons (MSNs) via promotion of cAMP production is the principal mechanism of action (MOA) of current antipsychotics with dopamine D2 receptor antagonism. Phosphodiesterase 10A (PDE10A) inhibitors activate both direct and indirect pathway MSNs...
Autores principales: | Suzuki, Kazunori, Harada, Akina, Suzuki, Hirobumi, Nakatani, Atsushi, Capuani, Clizia, Ugolini, Annarosa, Corsi, Mauro, Kaushal, Nidhi, Bobkov, Konstantin, Vekich, John, Doyle, Joseph, Kimura, Haruhide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887802/ http://dx.doi.org/10.1093/schbul/sby018.1010 |
Ejemplares similares
-
Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017) -
Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents
por: Harada, Akina, et al.
Publicado: (2019) -
Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015) -
Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020) -
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)